Oncology Medical News

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. Recommendations on the use of 18F-FDG PET in oncology

3. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials

4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer

5. Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Prognostic significance of S-phase kinase-associated protein 2 and p27kip1 in patients with diffuse large B-cell lymphoma: Effects of rituximab
Annals of Oncology, 11/10/09

Seki R et al. – Addition of rituximab to the CHOP regimen did not provide a beneficial outcome to patients with diffuse large B-cell lymphoma with high Skp2 expression and low p27 expression. Skp2 and p27 may be useful prognostic markers in the rituximab era.

Methods

Clinicopathologic features and immunohistochemical expression of Skp2 and p27 were studied retrospectively in 671 patients treated with cyclophosphamide, vincristine, doxorubicin and prednisolone (CHOP) or cyclophosphamide, vincristine, doxorubicin and prednisolone plus rituximab (R-CHOP)
Median follow-up periods 43.2 mos in CHOP group (n = 425) and 24.0 months in the R-CHOP group (n = 246)

Results

High Skp2 or low p27 expression correlated significantly with poor overall survival (OS) and progression-free survival in both treatment groups
Prognostic value of Skp2 or p27 expression independent of parameters included in International Prognostic Index by multivariate analysis
Patients with high Skp2 expression in combination with low p27 expression showed the worst survival

<< Previous
TNF superfamily gene polymorphism as prognostic factor in early...

Next >>
Phase I dose-finding study of paclitaxel with panitumumab,...